according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Fidaxomicin Solid Formulation

Manufacturer or supplier's details

Company : MSD

Address : 199 Wenhai North Road

HEDA, Hangzhou - Zhejiang Province - CHINA 310018

Telephone : 908-740-4000

Emergency telephone number : 86-571-87268110

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

Emergency Overview

Appearance : granules

Colour : White to light yellow Odour : No data available

Harmful if swallowed.

GHS Classification

Acute toxicity (Oral) : Category 4

GHS label elements

Hazard pictograms :

Signal word : Warning

Hazard statements : H302 Harmful if swallowed.

Precautionary statements : Prevention:

P264 Wash skin thoroughly after handling.

P270 Do not eat, drink or smoke when using this product.

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Response:

P301 + P312 + P330 IF SWALLOWED: Call a POISON CENTER/ doctor if you feel unwell. Rinse mouth.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Not classified based on available information.

Health hazards

Harmful if swallowed.

Environmental hazards

Not classified based on available information.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Fidaxomicin	873857-62-6	>= 50 -< 70
Cellulose	9004-34-6	>= 20 -< 30
Sodium benzoate	532-32-1	>= 1 -< 10
Citric acid	77-92-9	>= 1 -< 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.

Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting unless directed to do

so by medical personnel.

Get medical attention.

Rinse mouth thoroughly with water.

Never give anything by mouth to an unconscious person.

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Most important symptoms

and effects, both acute and delayed

Protection of first-aiders

Harmful if swallowed.

Contact with dust can cause mechanical irritation or drying of

Dust contact with the eyes can lead to mechanical irritation. First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Treat symptomatically and supportively. Notes to physician

5. FIREFIGHTING MEASURES

Suitable extinguishing media Water spray

> Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

Specific hazards during fire-

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod- :

ucts

Carbon oxides Metal oxides

Chlorine compounds

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec- : tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions Avoid release to the environment.

> Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres. Use only with adequate ventilation.

Local/Total ventilation Advice on safe handling

: Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Avoidance of contact : Oxidizing agents

Storage

Conditions for safe storage : Keep in properly labelled containers.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Packaging material : Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

		(Form of exposure)	ters / Permissible concentration	
Fidaxomicin	873857-62-6	TWA	200 μg/m3 (OEB 2)	Internal
Cellulose	9004-34-6	PC-TWA	10 mg/m3	CN OEL
		TWA	10 mg/m3	ACGIH
Sodium benzoate	532-32-1	TWA (Inhal- able particu- late matter)	2.5 mg/m3	ACGIH

Engineering measures : Use feasible engineering controls to minimize exposure to

compound.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type : Particulates type

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hand protection

Work uniform or laboratory coat.

Material : Chemical-resistant gloves

Hygiene measures : If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the work-

ing place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : granules

Colour : White to light yellow

Odour : No data available

Odour Threshold : No data available

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : Not applicable

Relative vapour density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation. Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation

Skin contact Ingestion Eye contact

Acute toxicity

Harmful if swallowed.

Product:

Acute oral toxicity : Acute toxicity estimate: 875.04 mg/kg

Method: Calculation method

Components:

Fidaxomicin:

Acute oral toxicity : LD50 (Rat): > 1,000 mg/kg

LD50 (Dog): > 120 mg/kg

Acute toxicity (other routes of:

administration)

LD50 (Rat): 200 mg/kg

Application Route: Intravenous

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Sodium benzoate:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Assessment: The substance or mixture has no acute oral tox-

icity

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: Based on data from similar materials

Citric acid:

Acute oral toxicity : LD50 (Mouse): 5,400 mg/kg

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:

Sodium benzoate:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Citric acid:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Sodium benzoate:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

Citric acid:

Species : Rabbit

Result : Irritation to eyes, reversing within 21 days

Method : OECD Test Guideline 405

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Sodium benzoate:

Test Type : Local lymph node assay (LLNA)

Exposure routes : Skin contact
Species : Mouse
Result : negative

Remarks : Based on data from similar materials

Germ cell mutagenicity

Not classified based on available information.

Components:

Fidaxomicin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro Test system: Chinese hamster ovary cells

Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Rat

Application Route: Intravenous

Result: negative

Test Type: comet assay

Species: Rat Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Result: negative

Sodium benzoate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosome aberration test in vitro

Result: positive

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Citric acid:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: in vitro micronucleus test

Result: positive

Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Sodium benzoate:

Species : Rat
Application Route : Ingestion
Exposure time : 24 month(s)
Result : negative

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Reproductive toxicity

Not classified based on available information.

Components:

Fidaxomicin:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Intravenous injection Fertility: NOAEL: 6.3 mg/kg body weight

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 12.6 mg/kg body weight Remarks: No significant adverse effects were reported

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Intravenous injection

Developmental Toxicity: NOAEL: 7 mg/kg body weight Remarks: No significant adverse effects were reported

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Sodium benzoate:

Effects on fertility : Test Type: Four-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Citric acid:

Effects on foetal develop-

ment

Test Type: One-generation reproduction toxicity study

Species: Rat

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Application Route: Ingestion

Result: negative

STOT - single exposure

Not classified based on available information.

Components:

Citric acid:

Assessment : May cause respiratory irritation.

STOT - repeated exposure

Not classified based on available information.

Repeated dose toxicity

Components:

Fidaxomicin:

Species : Rat

NOAEL : 90 mg/kg

Application Route : Oral

Exposure time : 28 D

Remarks : No significant adverse effects were reported

Species : Rat

NOAEL : 62.5 mg/kg

Application Route : Intravenous

Exposure time : 14 D

Species : Dog

NOAEL : 9,600 mg/kg

Application Route : Oral
Exposure time : 3 M
Symptoms : Vomiting

Remarks : No significant adverse effects were reported

Species : Monkey
NOAEL : 90 mg/kg
Application Route : Oral
Exposure time : 28 D

Remarks : No significant adverse effects were reported

Species : Juvenile rat
NOAEL : 200 mg/kg
Application Route : Oral
Exposure time : 28 D

Remarks : No significant adverse effects were reported

Cellulose:

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Sodium benzoate:

Species : Rat

NOAEL : 1,000 mg/kg
Application Route : Ingestion
Exposure time : 24 Months

Citric acid:

Species : Rat

NOAEL : 4,000 mg/kg LOAEL : 8,000 mg/kg Application Route : Ingestion Exposure time : 10 Days

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Fidaxomicin:

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, constipation

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Fidaxomicin:

icity)

Toxicity to algae/aquatic : EC50 (Anabaena flos-aquae (cyanobacterium)): > 18.4 mg/l

plants Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

NOEC (Anabaena flos-aquae (cyanobacterium)): 5.8 mg/l

NOEC (Pimephales promelas (fathead minnow)): 8.91 mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

Exposure time: 32 d

Method: OECD Test Guideline 210

Remarks: No toxicity at the limit of solubility

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC (Daphnia magna (Water flea)): 19.6 mg/l

Exposure time: 21 d

Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 50 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 5.9 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Sodium benzoate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 484 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l

Exposure time: 96 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 32

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Citric acid:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 100 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,535 mg/l

Exposure time: 24 h

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 2024/09/28 4750793-00011 Date of first issue: 2019/08/15 3.0

П

Sodium benzoate:

: Result: Readily biodegradable. Biodegradability

Biodegradation: 75 % Exposure time: 28 d

Citric acid:

Biodegradability Result: Readily biodegradable.

Biodegradation: 97 % Exposure time: 28 d

Method: OECD Test Guideline 301B

Bioaccumulative potential

Components:

Fidaxomicin:

Partition coefficient: n-

octanol/water

log Pow: 4.4

Sodium benzoate:

Partition coefficient: n-

octanol/water

: log Pow: 1.88

Citric acid:

Partition coefficient: n-

octanol/water

: log Pow: -1.72

Mobility in soil

Components:

Fidaxomicin:

Distribution among environ- : log Koc: 0.80

mental compartments

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Empty containers should be taken to an approved waste han-Contaminated packaging

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Environmentally hazardous : no

IATA-DGR

UN/ID No. : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
Packing instruction (cargo : Not applicable

aircraft)

Packing instruction (passen- : Not applicable

ger aircraft)

IMDG-Code

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable
EmS Code : Not applicable

Marine pollutant : no

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations

GB 6944/12268

UN number : Not applicable
Proper shipping name : Not applicable
Class : Not applicable
Subsidiary risk : Not applicable
Packing group : Not applicable
Labels : Not applicable

Marine pollutant : no

Special precautions for user

Not applicable

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

15. REGULATORY INFORMATION

National regulatory information

Law on the Prevention and Control of Occupational Diseases

Regulations on Safety Management of Hazardous Chemicals

Catalogue of Hazardous Chemicals : This product is not listed in the cata-

logue of hazardous chemicals and it does not meet the definition of hazardous chemicals and its principles

of determination.

dentification of Major Hazard Installations for Hazardous Chemicals (GB : Not listed

18218)

Hazardous Chemicals for Priority Management under : Not listed

SAWS

Regulations on Labour Protection in Workplaces where Toxic Substances are Used

Catalogue of Highly Toxic Chemicals : Not listed

Regulation of Environmental Management on the First Import of Chemicals and the Import and Export of Toxic Chemicals

China Severely Restricted Toxic Chemicals for Import : Not listed

and Export

Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/09/28

Further information

Sources of key data used to compile the Safety Data

Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CN OEL : Occupational exposure limits for hazardous agents in the

workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average

CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose): MARPOL - International Convention for the Prevention of Pollution from Ships: n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-

according to GB/T 16483 and GB/T 17519



Fidaxomicin Solid Formulation

Version Revision Date: SDS Number: Date of last issue: 2024/04/06 3.0 2024/09/28 4750793-00011 Date of first issue: 2019/08/15

rial is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN